"One advertiser falsely stated that ketamine was approved to treat depression, and then three falsely stated that ketamine was nonaddictive," Michael DiStefano, co-author of the study and an assistant professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences on the Anschutz Medical Campus, told UPI in a telephone interview.